Outlook Therapeutics, Inc.

Contributing Author

Recent Articles by Outlook Therapeutics, Inc.

Apr-22	Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules OTLK -9.14% GlobeNewswire
Apr-21	Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA (bevacizumab-vikg) OTLK -13.68% GlobeNewswire
Apr-07	Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA (bevacizumab-vikg) Accepted by FDA OTLK +6.18% GlobeNewswire
Mar-25	Outlook Therapeutics Announces Closing of $5.0 Million Public Offering OTLK GlobeNewswire
Mar-24	Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering OTLK -38.06% GlobeNewswire
Mar-23	Outlook Therapeutics Announces Proposed Public Offering OTLK -8.91% GlobeNewswire
Mar-16	Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note OTLK -10.69% GlobeNewswire
Mar-05	Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA (bevacizumab-vikg) OTLK GlobeNewswire
Feb-19	Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA (bevacizumab gamma) in Switzerland OTLK +6.10% GlobeNewswire
Feb-17	Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update OTLK -13.82% GlobeNewswire
Feb-11	Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter OTLK +11.52% GlobeNewswire
Jan-06	Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development OTLK GlobeNewswire
Dec-31	Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD OTLK -58.23% OTLK -15.28% GlobeNewswire
Dec-26	Outlook Therapeutics Announces New Employment Inducement Grants OTLK +8.79% OTLK GlobeNewswire
Dec-19	Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 OTLK GlobeNewswire
Nov-24	Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference OTLK GlobeNewswire
Nov-13	Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD OTLK +14.84% GlobeNewswire
Nov-03	Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 OTLK GlobeNewswire
Sep-29	Outlook Therapeutics Provides Update on Type A Meeting with FDA OTLK +9.27% GlobeNewswire
Sep-03	Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) OTLK GlobeNewswire
Sep-02	Outlook Therapeutics Requests Type A Meeting with FDA OTLK GlobeNewswire
Aug-28	Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD OTLK -54.11% GlobeNewswire
Aug-14	Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update OTLK +14.08% GlobeNewswire
Jul-24	Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase OTLK GlobeNewswire
Jul-22	Outlook Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference OTLK GlobeNewswire
Jul-01	Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer OTLK GlobeNewswire
Jun-18	Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event OTLK GlobeNewswire
Jun-10	Outlook Therapeutics Announces SMC Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD OTLK GlobeNewswire
Jun-02	Outlook Therapeutics Announces Commercial Launch of LYTENAVA (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD OTLK GlobeNewswire
May-23	Outlook Therapeutics Announces Pricing of $13.0 Million Public Offering OTLK GlobeNewswire
May-22	Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants OTLK GlobeNewswire
May-15	Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update OTLK GlobeNewswire

Outlook Therapeutics, Inc.

Recent Articles by Outlook Therapeutics, Inc.

Upgrade your Finviz experience